DOP2013000029A - Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos - Google Patents

Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos

Info

Publication number
DOP2013000029A
DOP2013000029A DO2013000029A DO2013000029A DOP2013000029A DO P2013000029 A DOP2013000029 A DO P2013000029A DO 2013000029 A DO2013000029 A DO 2013000029A DO 2013000029 A DO2013000029 A DO 2013000029A DO P2013000029 A DOP2013000029 A DO P2013000029A
Authority
DO
Dominican Republic
Prior art keywords
n3pglu
amiloide
peptidic
same
antibodies
Prior art date
Application number
DO2013000029A
Other languages
English (en)
Inventor
Ying Tang
Jirong Lu
Ronald Bradley Demattos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2013000029A publication Critical patent/DOP2013000029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos A3 anti-N3pGlu o fragmento de unión al antígeno de los mismos. Además, la presente invención proporciona el uso de los anticuerpos Aí3 anti-N3pGlu o fragmento de unión al antígeno de los mismos para el tratamiento de la enfermedad de Alzheimer.
DO2013000029A 2010-08-12 2013-02-05 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos DOP2013000029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37302610P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
DOP2013000029A true DOP2013000029A (es) 2013-03-15

Family

ID=44543826

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000029A DOP2013000029A (es) 2010-08-12 2013-02-05 Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos

Country Status (39)

Country Link
US (2) US8679498B2 (es)
EP (3) EP3042917B1 (es)
JP (2) JP5980207B2 (es)
KR (1) KR101498833B1 (es)
CN (2) CN105111308B (es)
AU (1) AU2011289629B2 (es)
BR (1) BR112013004056B8 (es)
CA (1) CA2805114C (es)
CL (1) CL2013000390A1 (es)
CO (1) CO6670526A2 (es)
CR (1) CR20130016A (es)
CY (2) CY1120144T1 (es)
DK (3) DK3339323T3 (es)
DO (1) DOP2013000029A (es)
EA (1) EA023021B1 (es)
EC (1) ECSP13012436A (es)
ES (3) ES2664128T3 (es)
FI (1) FIC20250038I1 (es)
GT (1) GT201300036A (es)
HR (3) HRP20160151T1 (es)
HU (2) HUE037524T2 (es)
IL (2) IL285226B2 (es)
LT (3) LT3042917T (es)
MA (1) MA34461B1 (es)
ME (3) ME02352B (es)
MX (2) MX342782B (es)
MY (2) MY163521A (es)
NO (2) NO3042917T3 (es)
NZ (2) NZ606095A (es)
PE (1) PE20130817A1 (es)
PH (1) PH12013500277A1 (es)
PL (3) PL3339323T3 (es)
PT (2) PT3042917T (es)
RS (3) RS59652B1 (es)
SG (2) SG10201509330XA (es)
SI (3) SI3339323T1 (es)
UA (1) UA107600C2 (es)
WO (1) WO2012021469A1 (es)
ZA (1) ZA201300437B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP3042917B1 (en) * 2010-08-12 2018-02-21 Eli Lilly and Company Anti-n3pglu amyloid beta peptide antibodies and uses thereof
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
US20170008955A1 (en) * 2014-02-03 2017-01-12 Cnj Holdings, Inc. Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
CN106604932B (zh) * 2014-07-10 2024-12-10 苏黎世大学 人白细胞介素-2的免疫刺激单克隆抗体
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
SMT202200050T1 (it) * 2015-09-23 2022-03-21 Regeneron Pharma Anticorpi bispecifici anti-cd3 ottimizzati e loro usi
KR20180100224A (ko) 2016-01-11 2018-09-07 노바르티스 아게 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740944A (zh) * 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN109562167A (zh) * 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
EP3500296A1 (en) 2016-08-18 2019-06-26 Eli Lilly and Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
MA46621A (fr) 2016-10-28 2021-06-02 H Lundbeck As Traitements combinés comprenant l'administration d'imidazopyrazinones
PL3532064T3 (pl) 2016-10-28 2020-11-16 H. Lundbeck A/S Terapie skojarzone obejmujące imidazopirazynony do leczenia zaburzeń psychiatrycznych i/lub poznawczych
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
PL3672631T3 (pl) 2017-08-22 2023-06-26 Biogen Ma Inc. Kompozycje farmaceutyczne zawierające przeciwciała przeciw beta-amyloidowi
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
PL3723807T3 (pl) 2017-12-14 2022-01-24 H. Lundbeck A/S Leczenie skojarzone obejmujące podawanie 1h-pirazolo­[4,3-b]pirydyn
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
WO2019154315A1 (zh) * 2018-02-11 2019-08-15 江苏豪森药业集团有限公司 抗b7-h4抗体、其抗原结合片段及其医药用途
AU2019233603B2 (en) * 2018-03-13 2025-06-26 Smivet B.V. Single domain antibodies binding to tetanus neurotoxin
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
CR20210492A (es) * 2019-03-26 2021-11-19 Janssen Pharmaceutica Nv ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2021257808A2 (en) * 2020-06-17 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Antibodies to fibroblast activation protein and b7h3
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
MX2023003836A (es) * 2020-10-02 2023-04-14 Lilly Co Eli Metodos para reducir el contenido de proteinas de celula huesped en procesos de purificacion de proteinas.
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
CN118139880A (zh) * 2021-10-22 2024-06-04 伊莱利利公司 O-连接的n-乙酰葡糖胺水解酶(oga)抑制剂联合治疗
WO2023077042A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
EP4423128A1 (en) 2021-10-29 2024-09-04 Eli Lilly and Company Compounds and methods targeting interleukin-34
KR20240099349A (ko) 2021-10-29 2024-06-28 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
CN118510800A (zh) 2021-10-29 2024-08-16 伊莱利利公司 靶向白细胞介素-34的化合物和方法
MX2024009597A (es) 2022-02-03 2024-08-15 Lilly Co Eli Imagenologia de tau regional para diagnosticar y tratar la enfermedad de alzheimer.
AU2023309007A1 (en) * 2022-07-21 2025-01-30 Eli Lilly And Company PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF
TW202440628A (zh) 2022-12-22 2024-10-16 瑞典商生物極公司 新抗體
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
UA93181C2 (ru) * 2004-02-23 2011-01-25 Эли Лилли Энд Компани СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
KR20110036809A (ko) 2008-06-12 2011-04-11 아피리스 아게 파킨슨병과 관련된 증상을 치료하기 위한 화합물
WO2010004434A2 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
AU2009273387B9 (en) * 2008-07-21 2015-06-11 Vivoryon Therapeutics N.V. Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
EP3042917B1 (en) * 2010-08-12 2018-02-21 Eli Lilly and Company Anti-n3pglu amyloid beta peptide antibodies and uses thereof

Also Published As

Publication number Publication date
JP6395755B2 (ja) 2018-09-26
CY1120144T1 (el) 2018-12-12
DK2603523T3 (en) 2016-03-21
IL285226A (en) 2021-09-30
NZ606095A (en) 2014-11-28
ECSP13012436A (es) 2013-03-28
CY1122458T1 (el) 2021-01-27
KR20130051989A (ko) 2013-05-21
ZA201300437B (en) 2014-06-25
AU2011289629B2 (en) 2014-07-03
CA2805114C (en) 2017-12-05
IL285226B2 (en) 2023-02-01
EA023021B1 (ru) 2016-04-29
MA34461B1 (fr) 2013-08-01
EP3339323B1 (en) 2019-11-13
EP3339323A1 (en) 2018-06-27
PE20130817A1 (es) 2013-07-18
ME03661B (me) 2020-07-20
PT3042917T (pt) 2018-05-02
ES2764728T3 (es) 2020-06-04
CO6670526A2 (es) 2013-05-15
US20130142806A1 (en) 2013-06-06
GT201300036A (es) 2014-07-16
FIC20250038I1 (fi) 2025-12-18
MY163521A (en) 2017-09-15
AU2011289629A1 (en) 2013-02-14
BR112013004056A2 (pt) 2020-08-04
EP2603523B1 (en) 2016-01-27
JP5980207B2 (ja) 2016-08-31
KR101498833B1 (ko) 2015-03-04
SG187586A1 (en) 2013-03-28
LT3042917T (lt) 2018-05-10
US20140065138A1 (en) 2014-03-06
MX342782B (es) 2016-10-12
ME02352B (me) 2016-06-20
MY181969A (en) 2021-01-15
CA2805114A1 (en) 2012-02-16
ES2564252T3 (es) 2016-03-21
HK1180703A1 (zh) 2013-10-25
EA201270813A1 (ru) 2013-05-30
RS57026B1 (sr) 2018-05-31
BR112013004056B8 (pt) 2022-10-18
HUE028678T2 (en) 2016-12-28
RS54685B1 (sr) 2016-08-31
SI3042917T1 (en) 2018-04-30
HRP20160151T1 (hr) 2016-03-11
NO2025056I1 (no) 2025-12-11
LTPA2026504I1 (es) 2026-02-10
SI3339323T1 (sl) 2019-12-31
CN105111308B (zh) 2019-03-12
UA107600C2 (uk) 2015-01-26
EP3042917B1 (en) 2018-02-21
NO3042917T3 (es) 2018-07-21
SI2603523T1 (sl) 2016-04-29
ME03032B (me) 2018-10-20
SG10201509330XA (en) 2015-12-30
HRP20180616T1 (hr) 2018-07-13
CR20130016A (es) 2013-03-21
EP2603523A1 (en) 2013-06-19
IL224030B (en) 2022-04-01
CN105111308A (zh) 2015-12-02
HUE037524T2 (hu) 2018-09-28
PL3339323T3 (pl) 2020-05-18
HRP20192233T1 (hr) 2020-03-06
WO2012021469A1 (en) 2012-02-16
BR112013004056B1 (pt) 2022-05-17
NZ626665A (en) 2016-04-29
PH12013500277A1 (en) 2017-04-21
MX2013001716A (es) 2013-10-28
PL3042917T3 (pl) 2018-07-31
LT3339323T (lt) 2020-02-10
JP2016179985A (ja) 2016-10-13
PL2603523T3 (pl) 2016-07-29
CN103068848A (zh) 2013-04-24
DK3042917T3 (en) 2018-04-23
CL2013000390A1 (es) 2014-03-21
DK3339323T3 (da) 2020-01-20
RS59652B1 (sr) 2020-01-31
PT3339323T (pt) 2020-01-14
US8679498B2 (en) 2014-03-25
JP2013536191A (ja) 2013-09-19
CN103068848B (zh) 2015-11-25
IL285226B (en) 2022-10-01
ES2664128T3 (es) 2018-04-18
EP3042917A1 (en) 2016-07-13
MX355268B (es) 2018-04-11
US8961972B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CL2019000643A1 (es) Anticuerpos de unión a cd3.
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
AU2018256498A1 (en) Antibodies to amyloid beta
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BR112014011594A2 (pt) anticorpos anti-il-36r
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201171060A1 (ru) Молекулы антител, обладающих специфичностью к человеческому ох40
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
BR112014011404A2 (pt) moléculas de anticorpos com especificidade para o ox40 humano
CU20120095A7 (es) Antagonistas de pcsk9
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
MX358249B (es) Proteínas de enlace al antígeno il-23 humanas.
CR20130126A (es) Anticuerpos anti-ox40 y métodos de uso de los mismos
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
AR124605A2 (es) Anticuerpos anti-il-36r
CY1117265T1 (el) Αντισωματα aνti-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
UA111322C2 (uk) Антитіло, що зв'язується переважно з позаклітинним доменом 4 людського csf-1r, і його застосування